ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control CompletedThis phase 3 trial tested whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside chemotherapy and radiation. The study me…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cocktail of drugs tested for tough esophageal cancer
Disease control CompletedThis study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other drugs in 90 people with advanced esophageal cancer that had already progressed after one prior treatment. The goal was to see if these combinations are safe and can shrink tumors …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo treatment matches standard for esophageal cancer
Disease control CompletedThis study looked at 200 people with advanced esophageal cancer to compare two treatments before surgery: immunotherapy combined with chemotherapy, versus chemotherapy plus radiation. Both treatments led to similar long-term survival rates. The immunotherapy combo may offer extra…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: NA • Sponsor: Yongtao Han • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC